In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Closed Loop Medicine: Pairing Software With Drugs To Optimize Dosing

In this episode of the In Vivo podcast, Hakim Yadi, CEO and co-founder of UK techbio Closed Loop Medicine, discusses how the company is pairing software and predictive analytics with medications old and new to tailor drug dosing.  

The Truly Transformational Potential Of AI Relies On The Data

Executives from several AI-focused biotechs emphasize that generating a truly innovative medicine, as opposed to a me-too drug, depends not just on the quantity, but on the quality of data used by the algorithm.

Latest Articles

Data Spotlight

Deals in Depth: April 2024

Seven $1bn+ alliances were penned in April. In the top alliance by deal value, Medincell entered a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications. Medincell will receive a $35m upfront payment and is eligible to receive up to $1.9bn in development and commercial milestones, plus mid-single to low-double-digit royalties on net sales.

Execs On The Move: April 2024

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

AMR, UTI, Breathomics And 3D Printing Technology Innovators Profiled At BioWales 2024

Breathomics, UTI diagnosis and advanced wound healing innovations were among the center stage technologies at BioWales in London 2024.

Deals Shaping The Industry, April 2024

An interactive look at pharma, medtech and diagnostics deals made during April 2024. Data courtesy of Biomedtracker.

See All
Growth

Entering Estonia: To Build Bigger Castles, You Need A Better Sandbox

Estonia is hoping to  create a brighter future by attracting leading startups to its borders, a process that will bring tax revenues, jobs and infrastructure.

BioBytes: AI-Related Deals In Q1 2024

BioBytes presents an overview of AI-related deals in Q1 2024. This is the first in a recurring series of quarterly deal updates.   

Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking

Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.

With A Transformational Year Underway, Insmed Ramps Up

With a reliable source of revenue in Arikayce and two key pulmonary late-stage trials reading out, Insmed aims to keep its commercial momentum going.

See All
Innovation

Closed Loop Medicine: Pairing Software With Drugs To Optimize Dosing

In this episode of the In Vivo podcast, Hakim Yadi, CEO and co-founder of UK techbio Closed Loop Medicine, discusses how the company is pairing software and predictive analytics with medications old and new to tailor drug dosing.  

Isomorphic Boasts Its Latest AI Tool

AlphaFold 3 is promising, but for now it stays in the hands of Isomorphic Labs and its partners.

AMR, UTI, Breathomics And 3D Printing Technology Innovators Profiled At BioWales 2024

Breathomics, UTI diagnosis and advanced wound healing innovations were among the center stage technologies at BioWales in London 2024.

Apogee CMO On New Approach To I&I Market

Having raised $345m in an IPO last year, prior to entering the clinic, Apogee Therapeutics has emerged as a startup to watch. Chief medical officer Carl Dambkowski, one of In Vivo’s 2024 Rising Leaders, shares more about the biotech’s pipeline strategy.

See All
Leadership

Execs On The Move: April 2024

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Agnė Vaitkevičienė: The Versatile CEO Driving Memel Biotech

Rising star Agnė Vaitkevičienė is juggling roles as the CEO of an emerging Lithuanian biotech, with work for a partner company, the national biotech trade association and much more. 

AI Medical Technology: A Rising Leader, One Year Later

AI Medical Technology has been busy, with publications demonstrating its lead product’s potential in melanoma, ongoing fundraising and board appointments.

Addex Gets Creative To Secure Funding And Its Future

Addex Therapeutics’ Tim Dyer has seen the company through 22 years of ups and downs. He has kept the company afloat, and recently did the same by spinning out a new company.

See All
Market Access

Is The IRA’s Impact On Innovation Being Overstated?

With the passage of the Inflation Reduction Act, many have questioned whether Medicare price negotiations will stifle small molecule innovation.

US FTC Targets Pharma Patent Abuse: What You Need to Know

The FTC is intensifying its crackdown on pharmaceutical companies' misuse of patent listings as industry seeks clearer guidelines.

For BMS, Launching New Products Is The Start Of The Battle

Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve access to lifesaving therapies. Payers and politicians must be persuaded to loosen their purse strings – and open their minds.

Winds Of Change Must Blow Through Welsh Health Care – Digital Chief At BioWales 2024

Wales must be better at adoption, said Mike Emery, the Welsh government’s digital and innovation officer for health and social care, in conversation with In Vivo.

See All
Market Intelligence

The Truly Transformational Potential Of AI Relies On The Data

Executives from several AI-focused biotechs emphasize that generating a truly innovative medicine, as opposed to a me-too drug, depends not just on the quantity, but on the quality of data used by the algorithm.

Deals in Depth: April 2024

Seven $1bn+ alliances were penned in April. In the top alliance by deal value, Medincell entered a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications. Medincell will receive a $35m upfront payment and is eligible to receive up to $1.9bn in development and commercial milestones, plus mid-single to low-double-digit royalties on net sales.

Will Actinium Be Big Pharma’s Next Radiopharmaceuticals Acquisition?

With big pharma on a radiopharmaceuticals buying spree, New York-based Actinium Pharmaceuticals has been pointed to as the next potential takeout target.

Why Are Clinical Development Success Rates Falling?

A recent analysis from Biomedtracker of clinical trial phase transitions between 2014 and 2023 suggests biopharma development success rates are falling. This poses several questions: what are the underlying reasons dragging success rates down and what does this mean for R&D productivity and the return on investment on pipeline spend?

See All
Recent Stories

Rezo’s Platform Could ‘Fundamentally Shift’ Drug Discovery

Rezo’s chief technology officer Sourav Bandyopadhyay discusses the company's focus on leveraging AI and machine learning to accelerate drug discovery and its potential for partnerships with big pharma.

The R&D Technology Stack: How Pharma Can Gain A Competitive Edge With AI, Data And Tech

The use of Artificial intelligence, data analytics and digital technologies hold the potential to transform pharmaceutical R&D and massively improve productivity. However, to achieve game-changing impact, the right technology infrastructure is required.

Isomorphic Boasts Its Latest AI Tool

AlphaFold 3 is promising, but for now it stays in the hands of Isomorphic Labs and its partners.

Deals in Depth: April 2024

Seven $1bn+ alliances were penned in April. In the top alliance by deal value, Medincell entered a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications. Medincell will receive a $35m upfront payment and is eligible to receive up to $1.9bn in development and commercial milestones, plus mid-single to low-double-digit royalties on net sales.

Entering Estonia: To Build Bigger Castles, You Need A Better Sandbox

Estonia is hoping to  create a brighter future by attracting leading startups to its borders, a process that will bring tax revenues, jobs and infrastructure.

Will Actinium Be Big Pharma’s Next Radiopharmaceuticals Acquisition?

With big pharma on a radiopharmaceuticals buying spree, New York-based Actinium Pharmaceuticals has been pointed to as the next potential takeout target.

Why Are Clinical Development Success Rates Falling?

A recent analysis from Biomedtracker of clinical trial phase transitions between 2014 and 2023 suggests biopharma development success rates are falling. This poses several questions: what are the underlying reasons dragging success rates down and what does this mean for R&D productivity and the return on investment on pipeline spend?

Is The IRA’s Impact On Innovation Being Overstated?

With the passage of the Inflation Reduction Act, many have questioned whether Medicare price negotiations will stifle small molecule innovation.

Execs On The Move: April 2024

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Agnė Vaitkevičienė: The Versatile CEO Driving Memel Biotech

Rising star Agnė Vaitkevičienė is juggling roles as the CEO of an emerging Lithuanian biotech, with work for a partner company, the national biotech trade association and much more. 

AI Medical Technology: A Rising Leader, One Year Later

AI Medical Technology has been busy, with publications demonstrating its lead product’s potential in melanoma, ongoing fundraising and board appointments.

UsernamePublicRestriction

Register